Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Conditions
- Leukemia, Lymphocytic, Chronic, B-CellLymphoma
- Interventions
- First Posted Date
- 2022-02-17
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 5
- Registration Number
- NCT05244070
- Locations
- 🇺🇸
Local Institution - 0026, Hackensack, New Jersey, United States
🇺🇸Local Institution - 0007, Boston, Massachusetts, United States
🇺🇸Local Institution - 0005, Birmingham, Alabama, United States
Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer
- Conditions
- Platinum-Resistant Ovarian Carcinoma
- Interventions
- First Posted Date
- 2022-02-04
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 33
- Registration Number
- NCT05225363
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Compare the Efficacy and the Safety of Taxotere and Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Samyang Biopharmaceuticals Corporation
- Target Recruit Count
- 26
- Registration Number
- NCT05207514
- Locations
- 🇰🇷
Sevrance Hospital, Seoul, Korea, Republic of
CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
- Conditions
- Metastatic HER2 Positive Gastroesophageal Junction Cancer
- Interventions
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Celularity Incorporated
- Target Recruit Count
- 1
- Registration Number
- NCT05207722
- Locations
- 🇺🇸
Georgetown, Washington, District of Columbia, United States
🇺🇸John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Scripps Health, La Jolla, California, United States
Minimizing Glucocorticoid Administration in Patients With Proliferative Lupus Nephritis
- Conditions
- Lupus Nephritis
- Interventions
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2022-03-03
- Lead Sponsor
- Institutul Clinic Fundeni
- Target Recruit Count
- 30
- Registration Number
- NCT05207358
- Locations
- 🇷🇴
Fundeni Clinical Institute, Bucharest, Romania
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma
- Conditions
- B-Cell Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 49
- Registration Number
- NCT05201248
- Locations
- 🇨🇳
Tianjin Cancer Hospital /ID# 228135, Tianjin, Tianjin, China
🇨🇳Peking University Third Hospital /ID# 228138, Beijing, Beijing, China
🇨🇳The Fifth Medical Center of PLA General Hospital /ID# 230520, Beijing, Beijing, China
Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis
- Conditions
- ANCA-associated Vasculitis
- Interventions
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd
- Target Recruit Count
- 100
- Registration Number
- NCT05197842
- Locations
- 🇨🇳
The Second hospital Of Anhui Medical University, Hefei, Anhui, China
🇨🇳Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Peking University First Hospital, Beijing, Beijing, China
A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma
- Conditions
- Non Hodgkin LymphomaDiffuse Large B Cell Lymphoma
- Interventions
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2022-03-11
- Lead Sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Target Recruit Count
- 36
- Registration Number
- NCT05200312
- Locations
- 🇨🇳
First affiliation hospital of nanjing medical university, Nanjing, Jiangsu, China
🇨🇳Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjin, Jiangsu, China
Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax
- Conditions
- Refractory Acute Lymphoblastic LeukemiaRelapsed Acute Lymphoblastic Leukemia
- Interventions
- Drug: VenetoclaxDrug: NavitoclaxDrug: DexamethasoneDrug: VincristineDrug: Calaspargase PegolDrug: DasatinibDrug: LeucovorinDrug: CytarabineDrug: Intrathecal TriplesBiological: BlinatumomabDrug: PegaspargaseDrug: MethotrexateDrug: MercaptopurineDrug: CyclophosphamideDrug: EtoposideDrug: Erwinia asparaginaseRadiation: Radiation
- First Posted Date
- 2022-01-14
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT05192889
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸St. Jude Children's Research Hospital, Memphis, Tennessee, United States
FT576 in Subjects With Multiple Myeloma
- Conditions
- Multiple MyelomaMyeloma
- Interventions
- Drug: FT576 (Allogenic CAR NK cells with BCMA expression)Drug: CyclophosphamideDrug: FludarabineDrug: BendamustineDrug: Daratumumab
- First Posted Date
- 2022-01-10
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Fate Therapeutics
- Target Recruit Count
- 31
- Registration Number
- NCT05182073
- Locations
- 🇺🇸
Texas Oncology-Medical City Dallas, Dallas, Texas, United States
🇺🇸Indiana University, Indianapolis, Indiana, United States
🇺🇸Virginia Oncology Associates, Norfolk, Virginia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.